Over the last years, DNA methylation profiling has emerged as a particularly appealing candidate technique for brain tumor diagnostics as it 1) allows for the simultaneous assessment of multiple markers (e.g., global DNA methylation levels as surrogate for IDH mutations, methylation status of the MGMT gene promoter, and copy numbers of chromosomal arms 1p19q) and 2) makes use of epigenetic signatures as tracers for tissues/cells of origin, which might aid in diagnostically challenging cases [12]. The gene discussed is MGMT; the disease is brain neoplasm.